Deficits in striatal dopamine release in cannabis dependence

Molecular Psychiatry

Volumn 22, Issue 1, 2017, Pages 68-75

  Van De Giessen, E ^a,b,c   Weinstein, J J ^a,b   Cassidy, C M ^a,b   Haney, M ^a,b   Dong, Z ^a,b   Ghazzaoui, R ^a,b   Ojeil, N ^a,b   Kegeles, L S ^a,b   Xu, X ^a,b   Vadhan, N P ^a,b,d   Volkow, N D ^e   Slifstein, M ^a,b   Abi Dargham, A ^a,b  

^a College of Phys and Surg ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d STONY BROOK UNIVERSITY   (United States)

^e NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMPHETAMINE; GLUTAMIC ACID; AMPHETAMINE; CANNABIS; DOPAMINE; ENDOCANNABINOID;

ADULT; ARTICLE; ATTENTION DISTURBANCE; CANNABIS ADDICTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DOPAMINE RELEASE; FEMALE; GLOBUS PALLIDUS; HIPPOCAMPUS; HUMAN; MALE; NEGATIVE SYNDROME; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITIVE SYNDROME; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; WORKING MEMORY; BRAIN; DRUG EFFECTS; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROCEDURES;

ADULT; AMPHETAMINE; BRAIN; CANNABIS; CORPUS STRIATUM; DEXTROAMPHETAMINE; DOPAMINE; ENDOCANNABINOIDS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MARIJUANA ABUSE; POSITRON-EMISSION TOMOGRAPHY;

EID: 84961392973     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2016.21     Document Type: Article

References (63)

1. Association AP. Diagnostic and Statistical Manual of Mental Disorders: DSM-5, 5th ed. American Psychiatric Publishing: Arlington, VA, USA, pp 2013.
2. Haberstick BC, Young SE, Zeiger JS, Lessem JM, Hewitt JK, Hopfer CJ. Prevalence and correlates of alcohol and cannabis use disorders in the United States: results from the national longitudinal study of adolescent health. Drug Alcohol Depend 2014; 136: 158-161.
3. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319-328.
4. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med 2014; 370: 2219-2227.
5. James A, James C, Thwaites T. The brain effects of cannabis in healthy adolescents and in adolescents with schizophrenia: a systematic review. Psychiatry Res 2013; 214: 181-189.
6. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990; 87: 1932-1936.
7. Lupica CR, Riegel AC, Hoffman AF. Marijuana and cannabinoid regulation of brain reward circuits. Br J Pharmacol 2004; 143: 227-234.
8. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009; 34: 759-766.
9. Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res 2001; 107: 173-177.
10. Bossong MG, Mehta MA, van Berckel BN, Howes OD, Kahn RS, Stokes PR. Further human evidence for striatal dopamine release induced by administration of 9-tetrahydrocannabinol (THC): selectivity to limbic striatum. Psychopharmacology 2015; 232: 2723-2729.
11. Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM. Can recreational doses of THC produce significant dopamine release in the human striatum? NeuroImage 2009; 48: 186-190.
12. Barkus E, Morrison PD, Vuletic D, Dickson JC, Ell PJ, Pilowsky LS et al. Does intravenous Delta9-tetrahydrocannabinol increase dopamine release? A SPET study. J Psychopharmacol 2011; 25: 1462-1468.
13. Trifilieff P, Martinez D. Imaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity. Neuropharmacology 2014; 76 Pt B: 498-509.
14. Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F. Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 2009; 56(Suppl 1): 3-8.
15. Urban NB, Slifstein M, Thompson JL, Xu X, Girgis RR, Raheja S et al. Dopamine release in chronic cannabis users: a [11c]raclopride positron emission tomography study. Biol Psychiatry 2012; 71: 677-683.
16. Mizrahi R, Suridjan I, Kenk M, George TP, Wilson A, Houle S et al. Dopamine response to psychosocial stress in chronic cannabis users: a PET study with [11C]-+-PHNO. Neuropsychopharmacology 2013; 38: 673-682.
17. Volkow ND, Wang GJ, Telang F, Fowler JS, Alexoff D, Logan J et al. Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. Proc Natl Acad Sci USA 2014; 111: E3149-E3156.
18. Bloomfield MA, Morgan CJ, Egerton A, Kapur S, Curran HV, Howes OD. Dopami-nergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry 2014; 75: 470-478.
19. Mizrahi R, Kenk M, Suridjan I, Boileau I, George TP, McKenzie K et al. Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology 2014; 39: 1479-1489.
20. Tziortzi AC, Haber SN, Searle GE, Tsoumpas C, Long CJ, Shotbolt P et al. Connectivity-based functional analysis of dopamine release in the striatum using diffusion-weighted MRI and positron emission tomography. Cereb Cortex 2014; 24: 1165-1177.
21. Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P et al. Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem 2006; 97: 1089-1103.
22. Dougherty DM, Mathias CW, Dawes MA, Furr RM, Charles NE, Liguori A et al. Impulsivity, attention, memory, and decision-making among adolescent marijuana users. Psychopharmacology 2013; 226: 307-319.
23. Landau SM, Lal R, O'Neil JP, Baker S, Jagust WJ. Striatal dopamine and working memory. Cereb Cortex 2009; 19: 445-454.
24. Wilkinson L, Tai YF, Lin CS, Lagnado DA, Brooks DJ, Piccini P et al. Probabilistic classification learning with corrective feedback is associated with in vivo striatal dopamine release in the ventral striatum, while learning without feedback is not. Hum Brain Mapp 2014; 35: 5106-5115.
25. de la Fuente-Sandoval C, Leon-Ortiz P, Favila R, Stephano S, Mamo D, Ramirez-Bermudez J et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 2011; 36: 1781-1791.
26. Kraguljac NV, White DM, Reid MA, Lahti AC. Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry 2013; 70: 1294-1302.
27. Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 2005; 19: 187-194.
28. Cachope R, Cheer JF. Local control of striatal dopamine release. Front Behav Neurosci 2014; 8: 188.
29. Gerdeman G, Lovinger DM. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 2001; 85: 468-471.
30. Sneider JT, Mashhoon Y, Silveri MM. A review of magnetic resonance spectro-scopy studies in marijuana using adolescents and adults. J Addict Res Ther 2013; (Suppl 4):pii: 010.
31. Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 1994; 51: 849-859, discussion 863-844.
32. Hasin DS, Trautman KD, Miele GM, Samet S, Smith M, Endicott J. Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. Am J Psychiatry 1996; 153: 1195-1201.
33. Sobell LC, Sobell MB. Timeline Followback: A Calendar Method for Assessing Alcohol and Drug Use. Addiction Research Foundation: Toronto, Ontario, Canada, 1996.
34. Heishman SJ, Singleton EG. Assessment of cannabis craving using the Marijuana Craving Questionnaire. Methods Mol Med 2006; 123: 209-216.
35. Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. J Clin Psychol 1995; 51: 768-774.
36. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276.
37. Hollingshead AB. Four factor index of social status. 1975, Working paper available from Department of Sociology, Yale University: New Haven, CT, USA.
38. Cohen JD, Forman SD, Braver TS, Casey BJ, Servan-Schreiber D, Noll DC. Activation of the prefrontal cortex in a nonspatial working memory task with functional MRI. Hum Brain Mapp 1994; 1: 293-304.
39. Knowlton BJ, Squire LR, Gluck MA. Probabilistic classification learning in amnesia. Learning Memory 1994; 1: 106-120.
40. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001; 21: 1034-1057.
41. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. NeuroImage 1996; 4(3 Pt 1): 153-158.
42. Albrecht DS, Skosnik PD, Vollmer JM, Brumbaugh MS, Perry KM, Mock BH et al. Striatal D(2)/D(3) receptor availability is inversely correlated with cannabis consumption in chronic marijuana users. Drug Alcohol Depend 2013; 128: 52-57.
43. Sevy S, Smith GS, Ma Y, Dhawan V, Chaly T, Kingsley PB et al. Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography. Psychopharmacology 2008; 197: 549-556.
44. Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry 2012; 17: 642-649.
45. Sneider JT, Pope HG Jr, Silveri MM, Simpson NS, Gruber SA, Yurgelun-Todd DA. Differences in regional blood volume during a 28-day period of abstinence in chronic cannabis smokers. Eur Neuropsychopharmacol 2008; 18: 612-619.
46. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers 2007; 4: 1770-1804.
47. Haney M, Bedi G, Cooper ZD, Glass A, Vosburg SK, Comer SD et al. Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status. Biol Psychiatry 2013; 73: 242-248.
48. Brody AL, Olmstead RE, London ED, Farahi J, Meyer JH, Grossman P et al. Smoking-induced ventral striatum dopamine release. Am J Psychiatry 2004; 161: 1211-1218.
49. Ceccarini J, De Hert M, Van Winkel R, Peuskens J, Bormans G, Kranaster L et al. Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. NeuroImage 2013; 79: 304-312.
50. Martin AB, Fernandez-Espejo E, Ferrer B, Gorriti MA, Bilbao A, Navarro M et al. Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neu-ropsychopharmacology 2008; 33: 1667-1679.
51. Van Waes V, Beverley JA, Siman H, Tseng KY, Steiner H. CB1 cannabinoid receptor expression in the striatum: association with corticostriatal circuits and developmental regulation. Front Pharmacol 2012; 3: 21.
52. Gallezot JD, Beaver JD, Gunn RN, Nabulsi N, Weinzimmer D, Singhal T et al. Affinity and selectivity of [(1)(1)C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. Synapse 2012; 66: 489-500.
53. Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006; 5: 25-43.
54. Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M et al. Imaging dopamine D-3 receptors in the human brain with positron emission tomography, [C-11]PHNO, and a selective D-3 receptor antagonist. Biol Psychiatry 2010; 68: 392-399.
55. Shotbolt P, Tziortzi AC, Searle GE, Colasanti A, van der Aart J, Abanades S et al. Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans. J Cereb Blood Flow Metab 2012; 32: 127-136.
56. Rabiner EA, Laruelle M. Imaging the D3 receptor in humans in vivo using [11C] (+)-PHNO positron emission tomography (PET). Int J Neuropsychopharmacol 2010; 13: 289-290.
57. Searle GE, Beaver JD, Tziortzi A, Comley RA, Bani M, Ghibellini G et al. Mathematical modelling of [(1)(1)C]-(+)-PHNO human competition studies. NeuroImage 2013; 68: 119-132.
58. Rabiner E, Slifstein M, Nobrega J, Plisson C, Huiban M, Raymond R et al. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)PHNO: studies in non-hman primates and transgenic mice. Synapse 2009; 63: 782-793.
59. Gallezot JD, Zheng MQ, Lim K, Lin SF, Labaree D, Matuskey D et al. Parametric imaging and test-retest variability of (1)(1)C-(+)-PHNO binding to D(2)/D(3) dopamine receptors in humans on the high-resolution research tomograph PET scanner. J Nucl Med 2014; 55: 960-966.
60. Bloomfield MA, Morgan CJ, Kapur S, Curran HV, Howes OD. The link between dopamine function and apathy in cannabis users: an [18 F]-DOPA PET imaging study. Psychopharmacology 2014; 231: 2251-2259.
61. Volkow ND, Wang GJ, Newcorn J, Telang F, Solanto MV, Fowler JS et al. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2007; 64: 932-940.
62. SAMHSA. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings, Center for Behavioral Health Statistics and Quality: Substance Abuse and Mental Health Services Administration: Rockville, MD, USA, 2014.
63. Heishman SJ, Singleton EG, Liguori A. Marijuana Craving Questionnaire: development and initial validation of a self-report instrument. Addiction 2001; 96: 1023-1034.